New Strong Sell Stocks for October 14th

Zacks added adidas, Celcuity and Collective Mining to its Rank #5 (Strong Sell) list. Consensus estimates for current-year earnings were revised down over the past 60 days by 5.1% for adidas, 15.3% for Celcuity and 31.8% for Collective Mining. The article also includes promotional material about quantum-computing stocks, without specific company or market data.

Analysis

The actionable signal is estimate deterioration, not the promotional quantum-computing pitch. For adidas (ADS), successive cuts may indicate weakening earnings expectations, but without the absolute forecast, valuation, or evidence on margins and inventory, a Strong Sell label alone is not a short thesis. For Celcuity (CELC), estimate revisions are especially hard to interpret for a clinical-stage company: trial/regulatory milestones and cash runway matter more than near-term earnings estimates. For Collective Mining (CNL), exploration results, permitting, funding needs, and metal prices are more decision-useful than consensus earnings revisions in isolation.

Near term, these labels could weigh on sentiment, but they may also reflect information already incorporated in prices; no valuation or positioning data support assuming further downside. Over 1–3 months, verify estimate changes against company guidance and relevant operating or clinical milestones. Over 6–18 months, commercial quantum adoption remains an uncertain, long-duration theme. The article offers no evidence that hyperscaler activity translates into material revenue or that quantum computing displaces classical infrastructure; near-term quantum spending could instead add R&D costs before producing meaningful returns. Avoid treating the named large-cap tech companies as direct quantum beneficiaries on this evidence alone.

Key Decisions for Investors

• No immediate trade from the Strong Sell additions alone. For ADS, consider a short only if subsequent guidance or reported operating metrics confirm deterioration and the share price fails to reflect it; falsify the thesis if estimates stabilize alongside improving margins or inventory trends.
• Keep CELC on a catalyst-and-cash-runway watchlist rather than trading the earnings-revision figure. Reassess after verified clinical or regulatory updates and review cash runway; positive data or adequate funding could invalidate a bearish read-through.
• Treat CNL as an exploration-risk and commodity-sensitive position, not a conventional earnings short. Before taking exposure, verify drill results, permitting, financing terms, and sensitivity to relevant metal prices; favorable resource evidence or improved funding access would challenge the downside case.
• Do not buy quantum-themed exposure based on this advertorial. Revisit only when named companies disclose measurable customer deployments, revenue, or economically meaningful workloads; absent that evidence, quantum remains a watch item, not a catalyst-based trade.